... References The FDA Approves Empaveli, New Treatment Option for C3G and Primary IC-MPGN — NephCure FDA Approves Apellis’ Empaveli (Pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older — Apellis Pharmaceuticals Empaveli (Pegcetacoplan) Injection, for Subcutaneous Use — Apellis Pharmaceuticals FDA Approves First Treatment ...
New Therapy Empaveli Protects Kidney Function in C3G, IC-MPGN
... References The FDA Approves Empaveli, New Treatment Option for C3G and Primary IC-MPGN — NephCure FDA Approves Apellis’ Empaveli (Pegcetacoplan) as the First C3G and Primary IC-MPGN Treatment for Patients 12 and Older — Apellis Pharmaceuticals Empaveli (Pegcetacoplan) Injection, for Subcutaneous Use — Apellis Pharmaceuticals FDA Approves First Treatment ...
... Food and Drug Administration Complement in Human Disease: Approved and Up-and-Coming Therapeutics — The Lancet Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial — Kidney International Reports FDA Approves Apellis’ Empaveli (Pegcetacoplan) as the First C3G and Primary ...
What Is C3 Glomerulopathy? 7 Facts
... Food and Drug Administration Complement in Human Disease: Approved and Up-and-Coming Therapeutics — The Lancet Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial — Kidney International Reports FDA Approves Apellis’ Empaveli (Pegcetacoplan) as the First C3G and Primary ...
... Recently, the FDA approved two treatments to help lower protein in the urine: A complement factor B inhibitor called iptacopan (Fabhalta) for adults with C3G A C3 inhibitor called pegcetacoplan (Empaveli) for people 12 and older with C3G and primary IC-MPGN Other complement blockers for these diseases are still being studied.Controlling InfectionsSometimes ...
Treating Rare Kidney Disease: Why the Underlying Cause Matters for C3G and IC-MPGN
... Recently, the FDA approved two treatments to help lower protein in the urine: A complement factor B inhibitor called iptacopan (Fabhalta) for adults with C3G A C3 inhibitor called pegcetacoplan (Empaveli) for people 12 and older with C3G and primary IC-MPGN Other complement blockers for these diseases are still being studied.Controlling InfectionsSometimes ...
... The second one, called pegcetacoplan (Empaveli), was approved in July for people 12 and older. Iptacopan is taken orally, while pegcetacoplan is given as a subcutaneous (under the skin) injection, usually twice a week. ...
Dense Deposit Disease: 5 Facts To Know
... The second one, called pegcetacoplan (Empaveli), was approved in July for people 12 and older. Iptacopan is taken orally, while pegcetacoplan is given as a subcutaneous (under the skin) injection, usually twice a week. ...
... It was the first drug approved by the FDA for this condition.In July 2025, the FDA approved another drug, pegcetacoplan (Empaveli), to treat both C3G and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). ...
Clinical Trials for Rare Kidney Disease: 6 Facts To Know
... It was the first drug approved by the FDA for this condition.In July 2025, the FDA approved another drug, pegcetacoplan (Empaveli), to treat both C3G and primary immune complex-mediated membranoproliferative glomerulonephritis (IC-MPGN). ...
... It’s taken as an oral tablet.A few months later, in July 2025, the FDA also approved pegcetacoplan (Empaveli) for people 12 years and older with C3G or a related kidney disease called primary immune complex MPGN (IC-MPGN). Pegcetacoplan has been used to treat PNH, but this is a separate approval for a new use. ...
7 C3 Glomerulopathy Treatment Options That Can Help
... It’s taken as an oral tablet.A few months later, in July 2025, the FDA also approved pegcetacoplan (Empaveli) for people 12 years and older with C3G or a related kidney disease called primary immune complex MPGN (IC-MPGN). Pegcetacoplan has been used to treat PNH, but this is a separate approval for a new use. ...
... Currently, there are also two FDA-approved treatments for C3 glomerulopathy: iptacopan (Fabhalta) and pegcetacoplan (Empaveli). These medicines target the complement system and are the first drugs made specifically for this disease. ...
Join
Your Privacy Choices
